Stoke Therapeutics Inc. (STOK)
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.
Stoke Therapeutics Q2 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission.
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June.
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen.
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report)'s share price was down 6.6% during mid-day trading on Friday following insider selling activity. The stock traded as low as $34.69 and last traded at $34.0860. Approximately 130,341 shares changed hands during trading, a decline of 82% from the average daily volume of 720,330 shares. The stock
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
Stoke Therapeutics' TANGO ASO platform can upregulate the functional allele, targeting haploinsufficiency diseases like Dravet and ADOA. This approach gives Zorevunersen disease-modifying features, which I believe will ultimately make it a very competitive asset for Dravet if approved. I believe Zorevunersen is the core value driver. And its Phase 3 EMPEROR plus four-year OLE data suggest durable seizure reductions.
